Zhou v. NextCure, Inc.

Background

Ye Zhou brought a proposed class action against NextCure, its officers, and several underwriters. The amended complaint asserted claims under Section 10(b) of the Securities Exchange Act and Securities and Exchange Commission Rule 10b-5, Section 20(a) of the Exchange Act, Sections 11 and 12(a) of the Securities Act, and Section 15 of the Securities Act.

The claims concerned NextCure’s cancer-drug candidate NC318 and its FIND-IO technology platform. Zhou alleged that NextCure’s November 2019 clinical-trial abstract omitted negative results from additional non-small-cell lung-cancer patients. Zhou also challenged later statements describing NC318 as promising and potentially useful for multiple cancer indications. In addition, Zhou alleged that the company’s initial and secondary-offering documents misleadingly described FIND-IO as unique, novel, and proprietary while failing to disclose allegations that the platform had been developed using confidential information from Immunaccel.

NextCure, its officers, and the underwriters moved to dismiss under Federal Rule of Civil Procedure 12(b)(6), which tests whether a complaint states a legally sufficient claim, and Rule 9(b), which requires fraud to be pleaded with particularity. The defendants also relied on the heightened pleading requirements of the Private Securities Litigation Reform Act.

Court’s Analysis

The court held that the clinical-trial abstract was not plausibly misleading. Zhou did not plead particular facts showing that the three additional patients were among the evaluable patients whose results were allegedly withheld. Alternatively, if the information became available after the abstract’s August 2019 data cutoff, the abstract stated that it contained interim results and that updated information would be presented at a conference four days later. The court also emphasized that the abstract disclosed the Phase 1 trial’s safety-focused design, its preliminary efficacy purpose, and its limitations.

The court treated several later statements—such as descriptions of NC318 as having “encouraging promise” or “potential”—as non-actionable corporate optimism, sometimes called puffery. The court also concluded that more specific statements about individual trial responses were not materially misleading because investors had received information about the trial’s limitations, including its lack of optimization for measuring efficacy, the absence of biopsies for many patients, and participants’ prior cancer treatments.

The court rejected the FIND-IO claims as well. Zhou relied on allegations from a separate complaint filed by Immunaccel, but those allegations had not been proven. The court ruled that repeating unproven allegations from another lawsuit did not supply sufficient facts for a securities-fraud claim. It further held that descriptions of the platform as “unique” and “novel” were too vague to be actionable, and that the complaint did not explain how the alleged use of unspecified confidential information made the platform’s descriptions misleading.

The court separately found that Zhou failed to plead scienter, meaning an intent to deceive or sufficiently reckless conduct. Because the complaint did not adequately allege a materially false or misleading statement or the required intent, the court did not reach the remaining elements of the Exchange Act fraud claims.

Related Claims and Disposition

Because Zhou did not plead a primary Section 10(b) violation, the court dismissed the Section 20 control-person claims. The court also dismissed the Securities Act claims under Sections 11 and 12(a) because they relied on the same statements and omissions that the court had found insufficient. The Section 15 control-person claim failed because it depended on an underlying Section 11 or Section 12(a) violation.

The court granted the defendants’ motion to dismiss the amended complaint. It directed the clerk to enter judgment and close the case. The opinion does not state that the dismissal was with or without prejudice.